NCT03442725 - Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

April 27, 2018

Study Completion Date

May 13, 2018

Conditions

Renal Impairment

Interventions

DRUG

Telotristat etiprate

Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.

Trial Locations (4)

A.T.C. s.a., Clinical Pharmacology Unit, CHU Sart-Tilman, Liège

CRS Clinical Research Services Kiel GmbH, Kiel

ARENSIA Exploratory Medicine Phase I Unit, Republican Clinical Hospital, Chisinau

ARENSIA Unit in Spitalul de Nefrologie, Bucharest